<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806324</url>
  </required_header>
  <id_info>
    <org_study_id>HL-040XC-US-001</org_study_id>
    <nct_id>NCT01806324</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>HanAll BioPharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HanAll BioPharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is:&#xD;
&#xD;
      To evaluate the pharmacokinetics and safety of an experimental combination tablet containing&#xD;
      20 mg atorvastatin and 50 mg losartan potassium when administered orally as a single dose to&#xD;
      healthy male subjects, compared with the concomitant administration of 20 mg atorvastatin and&#xD;
      50 mg losartan potassium tablets.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 ~ 48hr</time_frame>
    <description>To evaluate its bioequivalency in Cmax and AUC of each test group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>0~48HR</time_frame>
    <description>To evaluate bioequvalency of each group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>HL040XC(Atorvastatin+Losartan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL040XC lag time released combination drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan + Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coadministration group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL040XC</intervention_name>
    <description>single dose</description>
    <arm_group_label>HL040XC(Atorvastatin+Losartan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan + Atorvastatin</intervention_name>
    <description>Single dose</description>
    <arm_group_label>Losartan + Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects between 19 and 50 years of age, inclusive.&#xD;
&#xD;
          2. Subjects who weigh at least 121 pounds (55 kg), and are within ± 20% of their of ideal&#xD;
             body weight (IBW). IBW (kg) = [height (cm) - 100] x 0.9.&#xD;
&#xD;
          3. Subjects who don't have any congenital or chronic disease.&#xD;
&#xD;
          4. Subjects who don't have any clinically significant abnormality on vital sign&#xD;
             measurement, physical examination, clinical lab test, and ECG test at Screening.&#xD;
&#xD;
          5. Subjects who are able to read and understand the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have any history or presence of hypersensitivity to HMG-CoA reductase&#xD;
             inhibitors such as atorvastatin or angiotensin receptor blockers such as losartan.&#xD;
&#xD;
          2. Subjects who have any medical history that may affect the absorption, distribution,&#xD;
             metabolism, and excretion of study drugs (e.g., cardiovascular, respiratory, renal,&#xD;
             endocrinal, hematological, digestive, neurological, or psychiatric disease).&#xD;
&#xD;
          3. Subjects who have a creatinine clearance &lt; 80 mL/min, which is calculated by&#xD;
             Cockcroft-Gault equation: (140 - age) x (Wt in kg) / (72 x sCr).&#xD;
&#xD;
          4. Subjects who had a severe injury or surgery within 4 weeks prior to Screening.&#xD;
&#xD;
          5. Subjects who have a positive drug screen.&#xD;
&#xD;
          6. Subjects who take any prescription or herbal drug within 1 week prior to Screening.&#xD;
&#xD;
          7. Subjects who take any over-the counter (OTC) drug, which may affect this study or the&#xD;
             subject's safety according to the judgment of investigator, at Screening.&#xD;
&#xD;
          8. Subjects who take any herbal drug containing St. John's Wort or other drugs, which are&#xD;
             metabolized by CYP3A4 enzyme or inhibit or stimulate CYP enzyme (e.g., itraconazole,&#xD;
             ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitor,&#xD;
             nefazodone) within 4 weeks prior to Screening.&#xD;
&#xD;
          9. Subjects who have abnormal meal pattern that may affect the absorption, distribution,&#xD;
             metabolism, and excretion of study drugs (e.g., taking grapefruit juice over 1 L per&#xD;
             day).&#xD;
&#xD;
         10. Subjects who received an investigational product within 4 weeks prior to Screening.&#xD;
&#xD;
         11. Subjects who have donated blood within 6 weeks prior to Screening.&#xD;
&#xD;
         12. Subjects who consume alcohol over 21 units per week (1 unit = 150 mL of wine, 360 mL&#xD;
             of beer, or 45 mL of 40% alcohol) and can't accept the prohibition of alcohol during&#xD;
             this clinical study.&#xD;
&#xD;
         13. Subjects who smoke more than 10 cigarettes per day.&#xD;
&#xD;
         14. Subjects who have low blood pressure (systolic ≤ 100 mmHg or diastolic ≤ 65 mmHg) or&#xD;
             high blood pressure (systolic ≥ 150 mmHg or diastolic ≥ 95 mmHg) at Screening.&#xD;
&#xD;
         15. Subjects who test positive on serology HBsAg, HCV Ab, HIV Ab or VDRL at Screening.&#xD;
&#xD;
         16. Subjects who have active liver disease or elevated serum transaminase level higher&#xD;
             than 3 times of upper limit of normal.&#xD;
&#xD;
         17. Subjects who have the inability in the opinion of the investigator to comply with the&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <last_update_submitted>March 5, 2013</last_update_submitted>
  <last_update_submitted_qc>March 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

